NCT00102154
Withdrawn
Phase 3
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study of MK0928 in Healthy Adult Volunteers Participating in a 4-Hour Phase Advance Model of Transient Insomnia
ConditionsInsomnia
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Insomnia
- Sponsor
- H. Lundbeck A/S
- Primary Endpoint
- 4-hour advanced polysomnographic (PSG) recording session measuring wake time after sleep onset (WASO) and latency to persistent sleep (LPS); Safety and tolerability
- Status
- Withdrawn
- Last Updated
- 11 years ago
Overview
Brief Summary
A study to evaluate the safety and effectiveness of an investigational drug for insomnia (a sleep disorder).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy adults who are between the ages of 18 and 64
Exclusion Criteria
- •Adults who are diagnosed with insomnia
Outcomes
Primary Outcomes
4-hour advanced polysomnographic (PSG) recording session measuring wake time after sleep onset (WASO) and latency to persistent sleep (LPS); Safety and tolerability
Secondary Outcomes
- Daily sleep diary for visual analogue sleep quality and number of night awakenings (sNAW)
Similar Trials
Terminated
Phase 3
Elderly Primary Insomnia Polysomnographic Study (0928-002)(TERMINATED)Primary InsomniaNCT00094666H. Lundbeck A/S465
Terminated
Phase 3
Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED)Primary InsomniaNCT00420810H. Lundbeck A/S138
Completed
Phase 4
The Treatment of Insomnia in Patients With HIV DiseaseHIV InfectionsInsomniaNCT00465972Duke University44
Completed
Phase 3
An Investigational Study of MK0928 in Adult Outpatients With Insomnia (0928-014)(COMPLETED)InsomniaNCT00103818H. Lundbeck A/S900
Completed
Phase 2
MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)Alzheimer's DiseaseNCT00420420Merck Sharp & Dohme LLC144